Sarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of ($0.75), $0.93 better than the analyst estimate of ($1.68). Revenue for the quarter came in at $87 million versus the consensus estimate of $86.55 million.

“Having built out our multi-platform portfolio of genetic medicine in the prior two years and set out our ambition for Sarepta, we stated at the commencement of 2019 that this would be a year of execution. While we have much left to accomplish in 2019, I am pleased to report and quite proud that the Sarepta team executed brilliantly in the first quarter,” stated Doug Ingram, Sarepta’s president and chief executive officer.

Mr. Ingram continued, “Our Q1 2019 and recent accomplishments include the following: we continued to deliver on Exondys 51 and serve the Duchenne community; having fulfilled our commitment to commence our clinical process placebo-controlled trial for our micro-dystrophin gene therapy program by the fourth quarter of 2018, we made great progress on enrollment and dosing and are on track to complete dosing in the second quarter; we announced impressive results for our first LGMD2E cohort, particularly encouraging when one considers that the dose was one quarter of our micro-dystrophin program, reflecting the elegance of our construct and the potential for read through to other programs; fulfilling our promise to build a positive, science-driven relationship with the FDA and define an accelerated approval pathway for our RNA technology, the FDA accepted for filing our golodirsen package, informed us there would be no advisory committee at this time, and gave us priority review; we announced positive results for our third RNA program for casimersen; and we advanced our gene therapy manufacturing platform, moving to the late stage process development for our micro-dystrophin program, securing a dedicated 75,000 square foot manufacturing facility with Brammer, which we plan to be operational in 2019, and are working with Paragon and Catalent to deepen our relationship and create, either through a joint venture or otherwise, a second dedicated gene therapy facility. And beyond that, we continue to build our vision as an enduring genetic medicine leader; today we announced a new partnership with Nationwide Children’s Hospital to advance a gene therapy treatment for LGMD2A, the most common type of LGMD, a program perfectly aligned with our strategy to build out an enduring multi-therapeutic gene therapy engine.”

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.